PEG-PLGA from PolySciTech used in development of nanoparticles to treat stroke-induced brain injury

 

In 2021, 1 out of every 6 deaths from cardiovascular disease was caused by stroke and 87% of all strokes are ischemic strokes (https://www.cdc.gov/stroke/facts.htm). In addition to loss of blood-flow during ischemic stroke, brain damage is further aggravated by inflammation and other physiological responses. By reducing the inflammatory response, the damage from a stroke can be mitigated. Researchers at Chungnam National University, The University of Alabama, Mayo Clinic, Dankook University, Kyungpook National University, Indiana University School of Medicine, Seoul National University, Hallym University, Konyang University, Ajou University, Chungnam National University, and The University of Alabama used PLGA-PEG-COOH (AI078) and mPEG-PLGA (AK037) from PolySciTech Division of Akina, Inc (www.polyscitech.com) to develop nanoparticles decorated with AstroLa peptide for targeting to stroke-damaged portions of the brain and reducing inflammation. This research holds promise to reduce the damage resulting from an often fatal disease. Read more: Shin, Hyo Jung, Seung Gyu Choi, Fengrui Qu, Min-Hee Yi, Choong-Hyun Lee, Sang Ryong Kim, Hyeong-Geug Kim et al. "Peptide-mediated targeted delivery of SOX9 nanoparticles into astrocytes ameliorates ischemic brain injury." Nanoscale (2024). https://pubs.rsc.org/en/content/articlehtml/2023/nr/d3nr01318a

“Abstract: Astrocytes are highly activated following brain injuries, and their activation influences neuronal survival. Additionally, SOX9 expression is known to increase in reactive astrocytes. However, the role of SOX9 in activated astrocytes following ischemic brain damage has not been clearly elucidated yet. Therefore, in the present study, we investigated the role of SOX9 in reactive astrocytes using a poly-lactic-co-glycolic acid (PLGA) nanoparticle plasmid delivery system in a photothrombotic stroke animal model. We designed PLGA nanoparticles to exclusively enhance SOX9 gene expression in glial fibrillary acidic protein (GFAP)-immunoreactive astrocytes. Our observations indicate that PLGA nanoparticles encapsulated with GFAP:SOX9:tdTOM reduce ischemia-induced neurological deficits and infarct volume through the prostaglandin D2 pathway. Thus, the astrocyte-targeting PLGA nanoparticle plasmid delivery system provides a potential opportunity for stroke treatment. Since the only effective treatment currently available is reinstating the blood supply, cell-specific gene therapy using PLGA nanoparticles will open a new therapeutic paradigm for brain injury patients in the future.”

NEW: Corbion Purasorb® Polymers: https://akinainc.com/polyscitech/products/purasorb/

NEW: Ashland-TM products: https://akinainc.com/polyscitech/products/ashland/

BPR (Biotech Pharma Research) Conference (April 10, 2024, KPTC West Lafayette, IN) is a​ free ​scientific/​networking conference hosted by Akina (http://bprconference.com/​).